Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

References

• KornbergRDChromatin structure: a repeating unit of histones and DNAScience197418441398688714825889
   PubMed Web of Science ®Google Scholar
• KornbergRDStructure of chromatinAnnu Rev Biochem197746931954332067
   PubMed Web of Science ®Google Scholar
• MorrisonAJShenXChromatin remodelling beyond transcription: the INO80 and SWR1 complexesNat Rev Mol Cell Biol200910637338419424290
   PubMed Web of Science ®Google Scholar
• KouzaridesTChromatin modifications and their functionCell2007128469370517320507
   PubMed Web of Science ®Google Scholar
• JenuweinTAllisCDTranslating the histone codeScience200129355321074108011498575
   PubMed Web of Science ®Google Scholar
• SmithBCDenuJMChemical mechanisms of histone lysine and arginine modificationsBiochim Biophys Acta200917891455718603028
   PubMed Web of Science ®Google Scholar
• BernsteinBEMeissnerALanderESThe mammalian epigenomeCell2007128466968117320505
   PubMed Web of Science ®Google Scholar
• RothSYDenuJMAllisCDHistone acetyltransferasesAnnu Rev Biochem2001708112011395403
   PubMed Web of Science ®Google Scholar
• MinucciSPelicciPGHistone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNat Rev Cancer200661385116397526
   PubMed Web of Science ®Google Scholar
• SanchezRZhouMMThe role of human bromodomains in chromatin biology and gene transcriptionCurr Opin Drug Discov Devel2009125659665
   PubMedGoogle Scholar
• IzzoASchneiderRChatting histone modifications in mammalsBrief Funct Genomics201095–642944321266346
   PubMed Web of Science ®Google Scholar
• DuanHHeckmanCABoxerLMHistone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomasMol Cell Biol20052551608161915713621
   PubMed Web of Science ®Google Scholar
• Rada-IglesiasAEnrothSAmeurAButyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genesGenome Res200717670871917567991
   PubMed Web of Science ®Google Scholar
• de RuijterAJvan GennipAHCaronHNKempSvan KuilenburgABHistone deacetylases (HDACs): characterization of the classical HDAC familyBiochem J2003370Pt 373774912429021
   PubMed Web of Science ®Google Scholar
• GregorettiIVLeeYMGoodsonHVMolecular evolution of the histone deacetylase family: functional implications of phylogenetic analysisJ Mol Biol20043381173115050820
   PubMed Web of Science ®Google Scholar
• YangXJSetoEThe Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and menNat Rev Mol Cell Biol20089320621818292778
   PubMed Web of Science ®Google Scholar
• TannerKGLandryJSternglanzRDenuJMSilent information regulator 2 family of NAD-dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-riboseProc Natl Acad Sci USA20009726141781418211106374
   PubMed Web of Science ®Google Scholar
• MartinMKettmannRDequiedtFClass IIa histone deacetylases: regulating the regulatorsOncogene200726375450546717694086
   PubMed Web of Science ®Google Scholar
• MarksPAHistone deacetylase inhibitors: a chemical genetics approach to understanding cellular functionsBiochim Biophys Acta2010179910–1271772520594930
   PubMed Web of Science ®Google Scholar
• OckerMDeacetylase inhibitors – focus on non-histone targets and effectsWorld J Biol Chem201015556121540990
   PubMedGoogle Scholar
• GlozakMASenguptaNZhangXSetoEAcetylation and deacetylation of non-histone proteinsGene2005363152316289629
   PubMed Web of Science ®Google Scholar
• SpangeSWagnerTHeinzelTKrämerOHAcetylation of non-histone proteins modulates cellular signalling at multiple levelsInt J Biochem Cell Biol200941118519818804549
   PubMed Web of Science ®Google Scholar
• CressWDSetoEHistone deacetylases, transcriptional control, and cancerJ Cell Physiol2000184111610825229
   PubMed Web of Science ®Google Scholar
• OckerMSchneider-StockRHistone deacetylase inhibitors: signalling towards p21cip1/waf1Int J Biochem Cell Biol2007397–81367137417412634
   PubMed Web of Science ®Google Scholar
• FragaMFBallestarEVillar-GareaALoss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancerNat Genet200537439140015765097
   PubMed Web of Science ®Google Scholar
• ChoiJHKwonHJYoonBIExpression profile of histone deacetylase 1 in gastric cancer tissuesJpn J Cancer Res200192121300130411749695
   PubMedGoogle Scholar
• HalkidouKGaughanLCookSLeungHYNealDERobsonCNUpregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancerProstate200459217718915042618
   PubMed Web of Science ®Google Scholar
• ZhangZYamashitaHToyamaTHDAC6 expression is correlated with better survival in breast cancerClin Cancer Res200410206962696815501975
   PubMed Web of Science ®Google Scholar
• ZhangZYamashitaHToyamaTQuantitation of HDAC1 mRNA expression in invasive carcinoma of the breastBreast Cancer Res Treat2005941111616172792
   PubMed Web of Science ®Google Scholar
• ZhuPMartinEMengwasserJSchlagPJanssenKPGöttlicherMInduction of HDAC2 expression upon loss of APC in colorectal tumorigenesisCancer Cell20045545546315144953
   PubMed Web of Science ®Google Scholar
• WilsonAJByunDSPopovaNHistone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancerJ Biol Chem200628119135481355816533812
   PubMed Web of Science ®Google Scholar
• LaggerGO’CarrollDRemboldMEssential function of histone deacetylase 1 in proliferation control and CDK inhibitor repressionEMBO J200221112672268112032080
   PubMed Web of Science ®Google Scholar
• MontgomeryRLDavisCAPotthoffMJHistone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractilityGenes Dev200721141790180217639084
   PubMed Web of Science ®Google Scholar
• MontgomeryRLPotthoffMJHaberlandMMaintenance of cardiac energy metabolism by histone deacetylase 3 in miceJ Clin Invest2008118113588359718830415
   PubMed Web of Science ®Google Scholar
• VegaRBMatsudaKOhJHistone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesisCell2004119455556615537544
   PubMed Web of Science ®Google Scholar
• ChangSYoungBDLiSQiXRichardsonJAOlsonENHistone deacetylase 7 maintains vascular integrity by repressing matrix metalloproteinase 10Cell2006126232133416873063
   PubMed Web of Science ®Google Scholar
• ChangSMcKinseyTAZhangCLRichardsonJAHillJAOlsonENHistone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart developmentMol Cell Biol200424198467847615367668
   PubMed Web of Science ®Google Scholar
• HaberlandMMokalledMHMontgomeryRLOlsonENEpigenetic control of skull morphogenesis by histone deacetylase 8Genes Dev200923141625163019605684
   PubMed Web of Science ®Google Scholar
• LinRJSternsdorfTTiniMEvansRMTranscriptional regulation in acute promyelocytic leukemiaOncogene200120497204721511704848
   PubMed Web of Science ®Google Scholar
• MarksPABreslowRDimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugNat Biotechnol2007251849017211407
   PubMed Web of Science ®Google Scholar
• Campas-MoyaCRomidepsin for the treatment of cutaneous T-cell lymphomaDrugs Today (Barc)2009451178779520126671
   PubMed Web of Science ®Google Scholar
• PrinceHMBishtonMJHarrisonSJClinical studies of histone deacetylase inhibitorsClin Cancer Res200915123958396919509172
   PubMed Web of Science ®Google Scholar
• LaneAAChabnerBAHistone deacetylase inhibitors in cancer therapyJ Clin Oncol200927325459546819826124
   PubMed Web of Science ®Google Scholar
• MarksPAThe clinical development of histone deacetylase inhibitors as targeted anticancer drugsExpert Opin Investig Drugs201019910491066
   PubMed Web of Science ®Google Scholar
• Schneider-StockROckerMEpigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitorsIDrugs200710855756117665331
   PubMed Web of Science ®Google Scholar
• HuEDulESungCMIdentification of novel isoform-selective inhibitors within class I histone deacetylasesJ Pharmacol Exp Ther20033072720812975486
   PubMed Web of Science ®Google Scholar
• ParmigianiRBXuWSVenta-PerezGHDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulationProc Natl Acad Sci USA2008105289633963818606987
   PubMed Web of Science ®Google Scholar
• HaggartySJKoellerKMWongJCGrozingerCMSchreiberSLDomain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylationProc Natl Acad Sci USA200310084389439412677000
   PubMed Web of Science ®Google Scholar
• NamdarMPerezGNgoLMarksPASelective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agentsProc Natl Acad Sci USA201010746200032000821037108
   PubMed Web of Science ®Google Scholar
• TangWLuoTGreenbergEFBradnerJESchreiberSLDiscovery of histone deacetylase 8 selective inhibitorsBioorg Med Chem Lett20112192601260521334896
   PubMed Web of Science ®Google Scholar
• MarksPAXuWSHistone deacetylase inhibitors: potential in cancer therapyJ Cell Biochem2009107460060819459166
   PubMed Web of Science ®Google Scholar
• RichonVMSandhoffTWRifkindRAMarksPAHistone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylationProc Natl Acad Sci USA20009718100141001910954755
   PubMed Web of Science ®Google Scholar
• SandorVSenderowiczAMertinsSP21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228Br J Cancer200083681782510952788
   PubMed Web of Science ®Google Scholar
• ZhaoYTanJZhuangLJiangXLiuETYuQInhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein BimProc Natl Acad Sci USA200510244160901609516243973
   PubMed Web of Science ®Google Scholar
• HarikrishnanKNKaragiannisTCChowMZEl-OstaAEffect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartmentsCell Cycle20087446847618239454
   PubMed Web of Science ®Google Scholar
• KaragiannisTCEl-OstaAChromatin modifications and DNA double-strand breaks: the current state of playLeukemia200721219520017151702
   PubMed Web of Science ®Google Scholar
• AdimoolamSSirisawadMChenJThiemannPFordJMBuggyJJHDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombinationProc Natl Acad Sci USA200710449194821948718042714
   PubMed Web of Science ®Google Scholar
• ZhangYCarrTDimtchevAZaerNDritschiloAJungMAttenuated DNA damage repair by trichostatin A through BRCA1 suppressionRadiat Res2007168111512417722998
   PubMed Web of Science ®Google Scholar
• HotchkissRSStrasserAMcDunnJESwansonPECell deathN Engl J Med2009361161570158319828534
   PubMed Web of Science ®Google Scholar
• BoldenJEPeartMJJohnstoneRWAnticancer activities of histone deacetylase inhibitorsNat Rev Drug Discov20065976978416955068
   PubMed Web of Science ®Google Scholar
• SrivastavaRKKurzrockRShankarSMS-275 sensitizes TRAIL-resistant breast cancer cells, inhibits angiogenesis and metastasis, and reverses epithelial-mesenchymal transition in vivoMol Cancer Ther20109123254326621041383
   PubMed Web of Science ®Google Scholar
• RikiishiHAutophagic and apoptotic effects of HDAC inhibitors on cancer cellsJ Biomed Biotechnol2011201183026021629704
   PubMedGoogle Scholar
• ZhangYAdachiMKawamuraRImaiKBmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosisCell Death Differ200613112914015947789
   PubMed Web of Science ®Google Scholar
• XuYRegulation of p53 responses by post-translational modificationsCell Death Differ200310440040312719715
   PubMed Web of Science ®Google Scholar
• MaXEzzeldinHHDiasioRBHistone deacetylase inhibitors: current status and overview of recent clinical trialsDrugs200969141911193419747008
   PubMed Web of Science ®Google Scholar
• AdamsRHAlitaloKMolecular regulation of angiogenesis and lymphangiogenesisNat Rev Mol Cell Biol20078646447817522591
   PubMed Web of Science ®Google Scholar
• LinEYPollardJWTumor-associated macrophages press the angiogenic switch in breast cancerCancer Res200767115064506617545580
   PubMed Web of Science ®Google Scholar
• KimMSKwonHJLeeYMHistone deacetylases induce angiogenesis by negative regulation of tumor suppressor genesNat Med20017443744311283670
   PubMed Web of Science ®Google Scholar
• FathDMKongXLiangDHistone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alphaJ Biol Chem200628119136121361916543236
   PubMed Web of Science ®Google Scholar
• KongXLinZLiangDFathDSangNCaroJHistone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alphaMol Cell Biol20062662019202816507982
   PubMed Web of Science ®Google Scholar
• DuvicMTalpurRNiXPhase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood20071091313916960145
   PubMed Web of Science ®Google Scholar
• OlsenEAKimYHKuzelTMPhase IIb multicenter trial of vorinostat in patients with persistent progressive or treatment refractory cutaneous T-cell lymphomaJ Clin Oncol200725213109311517577020
   PubMed Web of Science ®Google Scholar
• KhanOLa ThangueNBDrug insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomasNat Clin Pract Oncol200851271472618839006
   PubMedGoogle Scholar
• KirschbaumMFrankelPPopplewellLPhase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma and mantle cell lymphomaJ Clin Oncol20112991198120321300924
   PubMed Web of Science ®Google Scholar
• LuuTHMorganRJLeongLA phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium studyClin Cancer Res200814217138714218981013
   PubMed Web of Science ®Google Scholar
• TraynorAMDubeySEickhoffJCVorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II studyJ Thorac Oncol20094452252619347984
   PubMed Web of Science ®Google Scholar
• VansteenkisteJVan CutsemEDumezHEarly phase II trial of oral vorinostat in relapsed or refractory breast colorectal or non-small cell lung cancerInvest New Drugs200826548348818425418
   PubMed Web of Science ®Google Scholar
• BlumenscheinGRJrKiesMSPapadimitrakopoulouVAPhase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid SAHA) in patients with recurrent and/or metastatic head and neck cancerInvest New Drugs2008261818717960324
   PubMed Web of Science ®Google Scholar
• ModesittSCSillMHoffmanJSBenderDPA phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group studyGynecol Oncol2008109218218618295319
   PubMed Web of Science ®Google Scholar
• SandorVBakkeSRobeyRWPhase I trial of the histone deacetylase inhibitor depsipeptide (FR901228 NSC 630176) in patients with refractory neoplasmsClin Cancer Res20028371872811895901
   PubMed Web of Science ®Google Scholar
• MarshallJLRizviNKauhJA phase I trial of depsipeptide (FR901228) in patients with advanced cancerJ Exp Ther Oncol20022632533212440223
   PubMedGoogle Scholar
• StadlerWMMargolinKFerberSMcCullochWThompsonJAA phase II study of depsipeptide in refractory metastatic renal cell cancerClin Genitourin Cancer200651576016859580
   PubMed Web of Science ®Google Scholar
• ByrdJCMarcucciGParthunMRA phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemiaBlood2005105395996715466934
   PubMed Web of Science ®Google Scholar
• KlimekVMFircanisSMaslakPTolerability pharmacodynamics and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromesClin Cancer Res200814382683218245545
   PubMed Web of Science ®Google Scholar
• SchrumpDSFischetteMRNguyenDMClinical and molecular responses in lung cancer patients receiving romidepsinClin Cancer Res200814118819818172270
   PubMed Web of Science ®Google Scholar
• KummarSGutierrezMGardnerERPhase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignanciesClin Cancer Res20071318 Pt 15411541717875771
   PubMed Web of Science ®Google Scholar
• GoreLRothenbergMLO’BryantCLA phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomasClin Cancer Res200814144517452518579665
   PubMed Web of Science ®Google Scholar
• GojoIJiemjitATrepelJBPhase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemiasBlood200710972781279017179232
   PubMed Web of Science ®Google Scholar
• BlumWKlisovicRBHackansonBPhase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemiaJ Clin Oncol200725253884389117679729
   PubMed Web of Science ®Google Scholar
• SorianoAOYangHFaderlSSafety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndromeBlood200711072302230817596541
   PubMed Web of Science ®Google Scholar
• AtmacaAAl-BatranSEMaurerAValproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trialBr J Cancer200797217718217579623
   PubMed Web of Science ®Google Scholar
• MünsterPMarchionDBicakuEPhase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational studyJ Clin Oncol200725151979198517513804
   PubMed Web of Science ®Google Scholar
• CandelariaMGallardo-RincónDArceCA phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumorsAnn Oncol20071891529153817761710
   PubMed Web of Science ®Google Scholar
• WellerMGorliaTCairncrossJGProlonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastomaNeurology201177121156116421880994
   PubMed Web of Science ®Google Scholar
• BanuelosCABanáthJPMacPhailSHZhaoJReitsemaTOlivePLRadiosensitization by the histone deacetylase inhibitor PCI-24781Clin Cancer Res20071322 Pt 16816682618006784
   PubMed Web of Science ®Google Scholar
• UndeviaSJanischLSchilskyRLPhase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781J Clin Oncol200826 Suppl14514
   Web of Science ®Google Scholar
• BarbettiVGozziniARovidaESelective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cellsOncogene200827121767177817891169
   PubMed Web of Science ®Google Scholar
• GueriniVBarbuiVSpinelliOThe histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F)Leukemia200822474074718079739
   PubMed Web of Science ®Google Scholar
• VivianiSBonfanteVFasolaCValagussaPGianniAMPhase II study of the histone-deacetylase inhibitor ITF2357 in relasped/refractory Hodgkin’s lymphoma patientsJ Clin Oncol200826 Suppl8532
   Google Scholar
• Le TourneauCSiuLLPromising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitorExpert Opin Investig Drugs200817812471254
   Web of Science ®Google Scholar
• SiuLLPiliRDuranIPhase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumorsJ Clin Oncol200826121940194718421048
   PubMed Web of Science ®Google Scholar
• Garcia-ManeroGAssoulineSCortesJPhase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemiaBlood2008112498198918495956
   PubMed Web of Science ®Google Scholar
• CrumpMAndreadisCAssoulineSTreatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II studyJ Clin Oncol200826 Suppl8528
   Web of Science ®Google Scholar
• BociekRGKuruvillaJProBIsotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 demonstrates clinical activity and safety in patients with relapsed/refractory classical Hodgkin lymphoma (HL)J Clin Oncol200826 Suppl8507
   Web of Science ®Google Scholar
• HurwitzHNelsonBO’DwyerPJPhase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumorsJ Clin Oncol200826 Suppl4625
   Google Scholar
• KwaFABalcerczykALicciardiPEl-OstaAKaragiannisTCChromatin modifying agents – the cutting edge of anticancer therapyDrug Discov Today20111613–1454354721664485
   PubMed Web of Science ®Google Scholar
• De los SantosMZambranoASánchez-PachecoAArandaAHistone deacetylase inhibitors regulate retinoic acid receptor beta expression in neuroblastoma cells by both transcriptional and posttranscriptional mechanismsMol Endocrinol200721102416242617622583
   PubMedGoogle Scholar
• De los SantosMZambranoAArandaACombined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cellsMol Cancer Ther2007641425143217431121
   PubMed Web of Science ®Google Scholar
• KimHJBaeSCHistone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugsAm J Transl Res20113216617921416059
   PubMed Web of Science ®Google Scholar
• KaragiannisTCHarikrishnanKNEl-OstaADisparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartmentsOncogene200726273963397117213813
   PubMed Web of Science ®Google Scholar
• KaragiannisTCHarikrishnanKNEl-OstaAThe histone deacetylase inhibitor, trichostatin A, enhances radiation sensitivity and accumulation of gammaH2A.XCancer Biol Ther20054778779316082178
   PubMed Web of Science ®Google Scholar
• Sanchez-GonzalezBYangHBueso-RamosCAntileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitorBlood200610841174118216675713
   PubMed Web of Science ®Google Scholar
• BriggsBVerverisKRoddALFoongLJSilvaFMKaragiannisTCPhotosensitization by iodinated DNA minor groove binding ligands: evaluation of DNA double-strand break induction and repairJ Photochem Photobiol B2011103214515221440453
   PubMed Web of Science ®Google Scholar
• SinghTRShankarSSrivastavaRKHDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinomaOncogene200524294609462315897906
   PubMed Web of Science ®Google Scholar
• KellyWKO’ConnorOAKrugLMPhase I study of an oral histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced cancerJ Clin Oncol200523173923393115897550
   PubMed Web of Science ®Google Scholar
• RubinEHAgrawalNGFriedmanEJA study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancerClin Cancer Res200612237039704517145826
   PubMed Web of Science ®Google Scholar
• Garcia-ManeroGYangHBueso-RamosCPhase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromesBlood200811131060106617962510
   PubMed Web of Science ®Google Scholar
• Lech-MarandaERobakEKoryckaARobakTDepsipeptide (FK228) as a novel histone deacetylase inhibitor: mechanism of action and anticancer activityMini Rev Med Chem20077101062106917979809
   PubMed Web of Science ®Google Scholar
• CaoDJWangZVBattiproluPKHistone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagyProc Natl Acad Sci USA2011108104123412821367693
   PubMed Web of Science ®Google Scholar
• ChoYKEomGHKeeHJSodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in ratsCirc J201074476077020208383
   PubMed Web of Science ®Google Scholar
• BogaardHJMizunoSHussainiAASuppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in ratsAm J Respir Crit Care Med2011183101402141021297075
   PubMed Web of Science ®Google Scholar
• KaragiannisTCLinAJVerverisKTrichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytesAging (Albany NY)201021065966820930262
   PubMedGoogle Scholar
• VerverisKRoddALTangMMEl-OstaAKaragiannisTCHistone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytesCell Mol Life Sci201168244101411421584806
   PubMed Web of Science ®Google Scholar
• VerverisKKaragiannisTCPotential non-oncological applications of histone deacetylase inhibitorsAm J Transl Res20113545446722046487
   PubMed Web of Science ®Google Scholar
• McKinseyTAOlsonENDual roles of histone deacetylases in the control of cardiac growthNovartis Found Symp2004259132141 discussion 141–145, 163–16915171251
   PubMedGoogle Scholar
• BacksJOlsonENControl of cardiac growth by histone acetylation/deacetylationCirc Res2006981152416397154
   PubMed Web of Science ®Google Scholar
• HaberlandMMontgomeryRLOlsonENThe many roles of histone deacetylases in development and physiology: implications for disease and therapyNat Rev Genet2009101324219065135
   PubMed Web of Science ®Google Scholar
• ZhangCLMcKinseyTAChangSAntosCLHillJAOlsonENClass II histone deacetylases act as signal-responsive repressors of cardiac hypertrophyCell2002110447948812202037
   PubMed Web of Science ®Google Scholar
• GuWRoederRGActivation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domainCell19979045956069288740
   PubMed Web of Science ®Google Scholar
• ThevenetLMéjeanCMoniotBRegulation of human SRY subcellular distribution by its acetylation/deacetylationEMBO J200423163336334515297880
   PubMed Web of Science ®Google Scholar
• YuanZLGuanYJChatterjeeDChinYEStat3 dimerization regulated by reversible acetylation of a single lysine residueScience2005307570726927315653507
   PubMed Web of Science ®Google Scholar
• BoyesJByfieldPNakataniYOgryzkoVRegulation of activity of the transcription factor GATA-1 by acetylationNature199839667115945989859997
   PubMed Web of Science ®Google Scholar
• HayakawaFTowatariMOzawaYTomitaAPrivalskyMLSaitoHFunctional regulation of GATA-2 by acetylationJ Leukoc Biol200475352954015001660
   PubMed Web of Science ®Google Scholar
• Martínez-BalbásMABauerUMNielsenSJBrehmAKouzaridesTRegulation of E2F1 activity by acetylationEMBO J200019466267110675335
   PubMed Web of Science ®Google Scholar
• SartorelliVPuriPLHamamoriYAcetylation of MyoD directed by PCAF is necessary for the execution of the muscle programMol Cell19994572573410619020
   PubMed Web of Science ®Google Scholar
• YaoYLYangWMSetoERegulation of transcription factor YY1 by acetylation and deacetylationMol Cell Biol200121175979599111486036
   PubMed Web of Science ®Google Scholar
• MunshiNMerikaMYieJSengerKChenGThanosDAcetylation of HMG I(Y) by CBP turns off IFN beta expression by disrupting the enhanceosomeMol Cell1998244574679809067
   PubMed Web of Science ®Google Scholar
• LührsHHockRSchauberJModulation of HMG-N2 binding to chromatin by butyrate-induced acetylation in human colon adenocarcinoma cellsInt J Cancer200297556757311807779
   PubMed Web of Science ®Google Scholar
• KiernanRBrèsVNgRWPost-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65J Biol Chem200327842758276612419806
   PubMed Web of Science ®Google Scholar
• LuoJLiMTangYLaszkowskaMRoederRGGuWAcetylation of p53 augments its site-specific DNA binding both in vitro and in vivoProc Natl Acad Sci USA200410182259226414982997
   PubMed Web of Science ®Google Scholar
• MunshiNAgaliotiTLomvardasSMerikaMChenGThanosDCoordination of a transcriptional switch by HMGI(Y) acetylationScience200129355321133113611498590
   PubMed Web of Science ®Google Scholar
• WangRCherukuriPLuoJActivation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylationJ Biol Chem200528012115281153415649887
   PubMed Web of Science ®Google Scholar
• FuMWangCReutensATP300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivationJ Biol Chem200027527208532086010779504
   PubMed Web of Science ®Google Scholar
• GaughanLLoganIRCookSNealDERobsonCNTip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptorJ Biol Chem200227729259042951311994312
   PubMed Web of Science ®Google Scholar
• WangCFuMAngelettiRHDirect acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivityJ Biol Chem200127621183751838311279135
   PubMed Web of Science ®Google Scholar
• YamagataTMitaniKOdaHAcetylation of GATA-3 affects T-cell survival and homing to secondary lymphoid organsEMBO J200019174676468710970860
   PubMed Web of Science ®Google Scholar
• ZhangWBiekerJJAcetylation and modulation of erythroid Krüppel-like factor (EKLF) activity by interaction with histone acetyltransferasesProc Natl Acad Sci USA19989517985598609707565
   PubMed Web of Science ®Google Scholar
• MarzioGWagenerCGutierrezMICartwrightPHelinKGiaccaME2F family members are differentially regulated by reversible acetylationJ Biol Chem200027515108871089210753885
   PubMed Web of Science ®Google Scholar
• JinYHJeonEJLiQLTransforming growth factor-beta stimulates p300-dependent RUNX3 acetylation which inhibits ubiquitination-mediated degradationJ Biol Chem200427928294092941715138260
   PubMed Web of Science ®Google Scholar
• JeongJWBaeMKAhnMYRegulation and destabilization of HIF-1alpha by ARD1-mediated acetylationCell2002111570972012464182
   PubMed Web of Science ®Google Scholar
• ItoAKawaguchiYLaiCHMDM2-HDAC1-mediated deacetylation of p53 is required for its degradationEMBO J200221226236624512426395
   PubMed Web of Science ®Google Scholar
• PatelJHDuYArdPGThe c-MYC oncoprotein is a substrate of the acetyltransferases hGCN5/PCAF and TIP60Mol Cell Biol20042424108261083415572685
   PubMed Web of Science ®Google Scholar
• GaughanLLoganIRNealDERobsonCNRegulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylationNucleic Acids Res2005331132615640443
   PubMed Web of Science ®Google Scholar
• KawaiHLiHAvrahamSJiangSAvrahamHKOverexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alphaInt J Cancer2003107335335814506733
   PubMed Web of Science ®Google Scholar
• GrönroosEHellmanUHeldinCHEricssonJControl of Smad7 stability by competition between acetylation and ubiquitinationMol Cell200210348349312408818
   PubMed Web of Science ®Google Scholar
• FuMWangCWangJAndrogen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression functionMol Cell Biol200222103373338811971970
   PubMed Web of Science ®Google Scholar
• ZhangWKadamSEmersonBMBiekerJJSite-specific acetylation by p300 or CREB binding protein regulates erythroid Krüppel-like factor transcriptional activity via its interaction with the SWI-SNF complexMol Cell Biol20012172413242211259590
   PubMed Web of Science ®Google Scholar
• BannisterAJMiskaEAGörlichDKouzaridesTAcetylation of importin-alpha nuclear import factors by CBP/p300Curr Biol200010846747010801418
   PubMed Web of Science ®Google Scholar
• ChenLFFischleWVerdinEGreeneWCDuration of nuclear NF-kappaB action regulated by reversible acetylationScience200129355351653165711533489
   PubMed Web of Science ®Google Scholar
• CohenHYLavuSBittermanKJAcetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosisMol Cell200413562763815023334
   PubMed Web of Science ®Google Scholar
• KovacsJJMurphyPJGaillardSHDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptorMol Cell200518560160715916966
   PubMed Web of Science ®Google Scholar